Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Abraxis Founder & Executive Chairman to Present at 7th Annual World Health Care Congress

Abstract:
Patrick Soon-Shiong, M.D. to Deliver Keynote "Transforming Health Care Now in the Developed and Developing Worlds" with Nobel Laureate Muhammad Yunus

Abraxis Founder & Executive Chairman to Present at 7th Annual World Health Care Congress

Los Angeles, CA | Posted on April 13th, 2010

Addressing over 2,000 government and industry health care experts gathering at the 7th Annual World Health Care Congress (WHCC) on Tuesday, April 13, 2010, Patrick Soon-Shiong, M.D., founder and executive chairman of Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, will present a vision for utilizing disruptive innovation for transforming healthcare in the United States and the developing world. The conference presentations are part of the 2010 banner, "Driving Strategy in an Uncertain Era of Health Reform," being held at the Gaylord National Resort and Convention Center in Washington, D.C. In a second address, with Vicki Seyfert-Margolis, Ph.D., senior advisor, Science Innovation and Policy, at the U.S. Food and Drug Administration, Dr. Soon-Shiong will present "FDA Update on Innovation in 21st Century Product Development."

For more information go to www.worldcongress.com.

####

About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab® platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 39 countries. The company continues to expand the nab® platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.

For more information, please click here

Contacts:
Abraxis BioScience, Inc.
Investors and Media Inquiries
Maili Bergman
310-883-1300


Media Inquiries
Zeno Group
Victoria Fort
202-361-0445

Copyright © Abraxis BioScience

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Searching for a nanotech self-organizing principle May 1st, 2016

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Nanomedicine

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Announcements

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Events/Classes

Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016

Introducing the RE標ORK Bio-inspired Robotics Summit in Berlin April 27th, 2016

ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center April 27th, 2016

Team builds first quantum cascade laser on silicon: Eliminates the need for an external light source for mid-infrared silicon photonic devices or photonic circuits April 21st, 2016

Nanobiotechnology

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic